AbbVie (NYSE:ABBV) Shares Acquired Rep. Marjorie Taylor Greene

Key Points

• Representative Marjorie Taylor Greene disclosed a purchase of AbbVie Inc. (NYSE:ABBV) shares worth between $1,001 and $15,000 on August 4th as part of her recent investment activities.
• AbbVie recently reported quarterly earnings of $2.97 per share, missing estimates, while also announcing a quarterly dividend of $1.64, reflecting an annual yield of 3.2%.
• AbbVie’s stock has seen optimistic ratings from analysts, with a consensus price target of $214.95 and a majority recommending a "buy" or "outperform" rating.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on August 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on August 4th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Palantir Technologies NASDAQ: PLTR on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 6/17/2025.
• Sold $1,001 - $15,000 in shares of lululemon athletica NASDAQ: LULU on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 6/6/2025.

AbbVie Trading Down 0.6%

Shares of NYSE ABBV traded down $1.1820 during trading on Tuesday, reaching $205.3880. The company had a trading volume of 1,864,026 shares, compared to its average volume of 6,675,077. The company's fifty day moving average price is $191.42 and its 200-day moving average price is $192.47. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $218.66. The stock has a market cap of $362.83 billion, a P/E ratio of 97.77, a PEG ratio of 1.33 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter last year, the firm posted $2.65 EPS. The company's quarterly revenue was up 6.6% on a year-over-year basis. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date was Tuesday, July 15th. AbbVie's payout ratio is 312.38%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company's stock, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.08% of the company's stock.

Institutional Trading of AbbVie

A number of institutional investors and hedge funds have recently modified their holdings of the business. Anchor Investment Management LLC increased its position in shares of AbbVie by 0.4% during the second quarter. Anchor Investment Management LLC now owns 85,278 shares of the company's stock valued at $15,829,000 after acquiring an additional 352 shares during the last quarter. Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie during the second quarter valued at approximately $39,000. Asset Dedication LLC increased its position in shares of AbbVie by 6.4% during the second quarter. Asset Dedication LLC now owns 11,780 shares of the company's stock valued at $2,187,000 after acquiring an additional 712 shares during the last quarter. Tyler Stone Wealth Management increased its position in shares of AbbVie by 6.4% during the second quarter. Tyler Stone Wealth Management now owns 5,154 shares of the company's stock valued at $957,000 after acquiring an additional 309 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of AbbVie by 22.2% during the second quarter. Geneos Wealth Management Inc. now owns 39,299 shares of the company's stock valued at $7,295,000 after acquiring an additional 7,135 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on ABBV. Raymond James Financial upped their price target on AbbVie from $227.00 to $236.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Daiwa Capital Markets upgraded AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 target price on the stock in a research report on Thursday, August 7th. Bank of America upped their target price on AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Morgan Stanley upped their target price on AbbVie from $250.00 to $255.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Finally, Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Five investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus target price of $214.95.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.